Team

We have ambition, talent, and conviction. We envision an exceptional future, and strive to make it real.

Our Leadership

Brian Armstrong

Co-founder

Brian Armstrong

Brian Armstrong is the co-founder and CEO of Coinbase, having grown it from inception to public company with thousands of employees and billions of dollars in revenue.

He is deeply passionate about accelerating science and improving human healthspan. He brings experience in software, machine learning, organization design, fundraising, leadership, and team building.

He holds a master’s degree in computer science and a bachelor’s degree in economics from Rice University.

Blake Byers

Co-founder

Blake Byers

Blake builds and invests in companies that move atoms and bits. His recent investments include Neuralink, Vial, Benchling and Freenome. Blake was most recently a General Partner at GV for a decade where he led investments in tech and healthcare companies. Some of his biotech investments include Forty Seven (Nasdaq: FTSV), Arcus (Nasdaq: RCUS), Denali (Nasdaq: DNLI), and Grail (acquired by Illumina). Blake’s incubations include Pact Pharma, a neoantigen T cell therapy company.

Blake received a PhD and MS in bioengineering from Stanford University and holds a BS in biomedical engineering and BS in economics from Duke University.

Greg Johnson

Head of Machine Learning

Greg Johnson

Greg accelerates research by using statistical methods to predict the outcomes of biological experiments.

Prior to NewLimit, Greg led and contributed to special projects at Amazon. Before that, he led the development of novel machine learning methods at the Allen Institute for Cell Science. Greg is best known for inventing technology to label diverse tissue structures in silico and developing generative models to propose and prioritize hypotheses for high-throughput experimentation.

Greg received a PhD in computational biology and a MS in biomedical engineering from Carnegie Mellon University, and BS in bioengineering from California Lutheran University.

Jacob Kimmel

Head of Research

Jacob Kimmel

Jacob uses genomics and machine learning methods to identify and manipulate the genetic programs that define cell identity.

Prior to NewLimit, Jacob led a research laboratory focused on epigenetic reprogramming as a Principal Investigator and Computational Fellow at Calico. His program developed methods to infer and perturb cell identity programs and leveraged these tools to discover reprogramming strategies that restore youthful features in aged cells.

Jacob received a Ph.D. in stem cell biology from the University of California San Francisco.

Our Scientific Advisors

Mark M. Davis

Scientific Advisor

Mark M. Davis

Mark M. Davis is the Director of the Stanford Institute for Immunology, Transplantation and Infection, a professor of microbiology and immunology, and a Howard Hughes Medical Institute Investigator.

Dr. Davis is well known for identifying many of the T-cell receptor genes, which are responsible for the ability of these cells to recognize a diverse repertoire of antigens. His current research focuses on obtaining a “systems level” understanding of the human immune system, including the steady state and vaccine responses of old and young subjects.

Dr. Davis received a BA from Johns Hopkins University, and a PhD from the California Institute of Technology.

Alex Marson

Scientific Advisor

Alex Marson

Alex Marson is a professor at UCSF, scientific director of human health at the Innovative Genomics Institute (IGI), and head of the Gladstone-UCSF Institute of Genomic Immunology. Dr. Marson’s research goal is to understand the genetic circuits that control human immune cell function, and his team has pioneered new CRISPR gene editing technologies that offer more precise ways to rewrite DNA programs in human immune cells.

Dr. Marson received an AB and an MD from Harvard, a PhD from MIT, and completed his internal medicine residency at Brigham and Women’s Hospital, and an infectious diseases fellowship at UCSF.

E. John Wherry

Scientific Advisor

E. John Wherry

Dr. E. John Wherry is the Barbara Schiffrin President’s Distinguished Professor at the Perelman School of Medicine at the University of Pennsylvania. John also serves as the Chair of the Department of Systems Pharmacology and Translational Therapeutics and the Director of the Institute for Immunology at the Perelman School of Medicine.

John’s work has pioneered the field of T cell exhaustion and revealed the molecular mechanisms of diverse T cell identity programs. Among other contributions, his group has defined the transcriptional program of T cell exhaustion, revealed the functional characteristics of exhausted T cells, and discovered the role of inhibitory receptors such as PD-1 in the exhaustion program. The Wherry lab has demonstrated that exhaustion programs play an important role in limiting the effectiveness of adaptive immune responses to both chronic infection and cancer and explored checkpoint blockade mechanisms to re-invigorate exhausted cells. To enable these discoveries, the Wherry lab has employed emerging epigenetic profiling technologies to define T cell identity programs, identify the molecular drivers of these transcriptional programs, and delineate distinct T cell fates.

Dr. Wherry holds a Ph.D. in Immunology from the Thomas Jefferson University and a B.S. from the Pennsylvania State University.

Our Investors

No items found.